What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

References

• King CR, Krauss MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science229(4717), 974–976 (1985).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clarke GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist14(4), 320–368 (2009).
   PubMed Web of Science ®Google Scholar
• Cuello M, Ettenberg SA, Clark AS et al. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erb-2. Cancer Res.61(12), 4892–4900 (2001).
   PubMed Web of Science ®Google Scholar
• Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp. Cell. Res.304(2), 604–619 (2005).
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Sarotto I et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene24(18), 3002–3010 (2005).
   PubMed Web of Science ®Google Scholar
• Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her-2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res.61(12), 4744–4749 (2001).
   PubMed Web of Science ®Google Scholar
• Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)–Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol.20(9), 3210–3223 (2000).
   PubMed Web of Science ®Google Scholar
• Marches R, Uhr JW. Enhancement of the p27Kp1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int. J. Cancer112(3), 492–501 (2004).
   PubMed Web of Science ®Google Scholar
• Le XF, Pruefer F, Bast RC Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle4(1), 87–95 (2005).
   PubMed Web of Science ®Google Scholar
• Asanuma H, Torigoe T, Kamiguchi K et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res.65(23), 11018–11025 (2005).
   PubMed Web of Science ®Google Scholar
• Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin. Cancer Res.12(3 Pt 1), 845–853 (2006).
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorma CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA89(10), 4285–4289 (1992).
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.6(4), 443–446 (2000).
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res.10(17), 5650–5655 (2004).
   PubMed Web of Science ®Google Scholar
• Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene18(13), 2241–2251 (1999).
   PubMed Web of Science ®Google Scholar
• Pegram MD, Konecmy GE, O’Collaghan C, Beryt M, Pietras R, Slamon D. Rational of combinations of trastuzumab with chemotherapy drugs used in treatment of breast cancer. J. Natl Cancer Inst.96(10), 739–749 (2004).
   PubMed Web of Science ®Google Scholar
• Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotère) in HER-2 expressing human cancer cell lines. Ann. Oncol.13(11), 1743–1748 (2002).
   PubMed Web of Science ®Google Scholar
• Hamberg P, Bontenbal M, Vernhout RM et al. Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (multicenter BOOG-study; 2002–02). Breast Cancer Res. Treat.76(Suppl. 1), 1077 (2007).
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi RS et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first line treatment: the M77001 Study Group. J. Clin. Oncol.23(19), 4265–4274 (2005).
   PubMed Web of Science ®Google Scholar
• Robert N, Leyland-Jones B, Asmar L et al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol.24(18), 2786–2792 (2006).
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Rowland KM et al. Two concurrent Phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin. Breast Cancer6(5), 425–432 (2005).
   PubMedGoogle Scholar
• Valero V, Forbes J, Pegram MD et al. Multicenter Phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first-line chemotherapy for patient with HER2-gene-amplified metastatic breast cancer (BCIRG 007 Study): two highly active therapeutic regimens. J. Clin. Oncol.29(2), 149–156 (2011).
   PubMed Web of Science ®Google Scholar
• Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA Study. J. Clin. Oncol.29(3), 264–271 (2011).
   PubMed Web of Science ®Google Scholar
• Bayo-Calero JL, Mayordomo JI, Sanchez-Rovira P et al. A Phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clin. Breast Cancer8(3), 264–268 (2008).
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 Study. J. Clin. Oncol.27(12), 1999–2006 (2009).
   PubMed Web of Science ®Google Scholar
• Moulder S, Li H, Wang M et al. A Phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patient with HER-2 positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res. Treat.119(3), 663–671 (2010).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin. Breast Cancer5(2), 142–147 (2004).
   PubMedGoogle Scholar
• Bartsch R, Wenzel C, Gampenrieder SP et al. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother. Pharmacol.62(5), 903–910 (2008).
   PubMed Web of Science ®Google Scholar
• Loesch D, Asmar L, McIntyre K et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER-2 positive disease) in patients with metastatic breast cancer. Clin. Breast Cancer8(2), 178–186 (2008).
   PubMed Web of Science ®Google Scholar
• Yardley DA, McLeod M, Schreiber F et al. A Phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest.28(9), 925–931 (2010).
   PubMed Web of Science ®Google Scholar
• Bianchi G, Albanell J, Eiermann W et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin. Cancer Res.9(16 Pt 1), 5944–5951 (2003).
   PubMed Web of Science ®Google Scholar
• Untch M, Muscholl M, Tjulandin S et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, cyclophosphamide, and epirubicin (HERCULES) trial. J. Clin. Oncol.28(9), 1473–1480 (2010).
   PubMed Web of Science ®Google Scholar
• Nistico C, Bria E, Vaccaro V et al. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-Phase II study aimed at cardiotoxicity. Anticancer Drugs20(2), 109–114 (2009).
   PubMed Web of Science ®Google Scholar
• Gennari A, De Tursi M, Carella C et al. Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Res. Treat.115(1), 131–136 (2009).
   PubMed Web of Science ®Google Scholar
• Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol.24(18), 2773–2278 (2006).
   PubMed Web of Science ®Google Scholar
• Stickeler E, Klar M, Watermann D et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter Phase II trial. Breast Cancer Res. Treat.117(3), 591–598 (2009).
   PubMed Web of Science ®Google Scholar
• Venturini M, Bighin C, Puglisi F et al. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast19(5), 333–338 (2010).
   PubMed Web of Science ®Google Scholar
• Campone M, Juin P, André F, Bachelot T. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit. Rev. Oncol. Hematol.78(3), 195–205 (2011).
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol.28(7), 1124–1130 (2010).
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Fumoleau P et al. Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009.
   Google Scholar